Publications by authors named "Migdalia E Gonzalez"
Cancers (Basel)
September 2024
Article Synopsis
- Endocrine therapy combined with CDK4/6 inhibitors is the standard first-line treatment for hormone receptor-positive metastatic breast cancer, but resistance can develop, requiring alternative therapies like alpelisib.
- Researchers explored the effects of combining alpelisib with the PLK1 inhibitor onvansertib in preclinical models to improve treatment outcomes for patients with resistant -mutant HR+ breast cancer.
- Results showed that the combination significantly inhibited cancer cell growth and enhanced apoptosis in resistant models, suggesting it could be an effective new treatment strategy that needs further clinical testing.
